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Abstract
Extensive mutagenesis has defined distinct functional domains in the HIV-1 matrix domain (MA). In an attempt to more clearly define
functions of regions of MA which affect viral entry, we analyzed mutations in the N-terminal basic and the C-terminal helical domains.
Deletions of 8–10 amino acid residues of the C-terminal fifth helix of MA resulted in viruses that were only mildly defective in infectivity and
fusion. The defect exhibited by these mutations could largely be attributed to a reduction in levels of viral envelope incorporated into mature
virions. Truncation of the gp41 cytoplasmic tail (gp41CT) could rescue the phenotype of one of these mutants. In contrast, mutations of multiple
basic residues in the N-terminus of MA were severely defective in both infectivity and fusion. While these mutations induce severe envelope
incorporation defects, they also result in virus crippled at a post-entry step, since truncation of the gp41CT could not rescue the infectivity
defect.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1 Matrix; Fusion; Envelope IncorporationIntroduction
The HIV-1 Pr55Gag polyprotein precursor is the major struc-
tural determinant of particle formation. Pr55Gag is sufficient for
the assembly and release of non-infectious virus-like particles
(VLPs). Proteolytic cleavage of Pr55Gag by the viral protease
(PR) produces the mature 17 kD matrix (MA), 24 kD capsid
(CA), 7 kD nucleocapsid (NC), and p6 domains.
MA is involved in multiple steps of the HIV-1 replication
cycle and mutational analysis has identified several domains
within MA which regulate these various functions (Fig. 1A)
(Freed, 1998). MA is important for both early viral replication
events, including entry, as well as late assembly events. MA is
involved in viral entry by regulating fusion, especially that of
immature particles, with target cell membranes (Murakami et al.,
2004; Wyma et al., 2004). In addition to modulating the un-⁎ Corresponding author. Fax: +1 314 747 2120.
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doi:10.1016/j.virol.2007.06.046coating of viral cores post-entry, MA is also a component of both
the viral reverse transcription and pre-integration complexes
(PIC) (Gallay et al., 1995). Two proposed nuclear localization
sequences in MA may aid in nuclear import of the PIC
(Bukrinsky et al., 1993; Haffar et al., 2000).
MA is necessary for the proper assembly of infectious virions.
Export of viral RNA from the nucleus is mediated, in part, by a
nuclear export signal inMA (Dupont et al., 1999).MA also plays
a critical role in the membrane binding and targeting of Pr55Gag
during assembly. Membrane binding capacity is conferred to the
protein by the N-myristylation signal found in the first 6 amino
acids (aa) of MA (Bryant and Ratner, 1990; Freed et al., 1994;
Spearman et al., 1994). Targeting to the plasma membrane (PM)
or the multivesicular bodies (MVB), from which virions
assemble and bud, appears to be at least partially regulated by
the concerted actions of the 17 amino acid basic domain (aa 14–
31) and aa 80–84 in MA (Freed, 1998; Freed and Martin, 2001;
Freed et al., 1994). Upon synthesis of Pr55Gag, the myristate
moiety (myr) is sequestered by the immature MA domain.
Association with lipid raft-associated phosphatidylinositol-
Fig. 1. N-terminal basic domain mutations and C-terminal deletions in MA. (A) Mutations used in this study are shown in relation to known functional domains in MA.
The MA18,20,22 mutation is comprised of substitutions K18I, R20G, and R22A. The MA32,33 mutation is comprised of substitutions K32I and H33L. D9 and D10
are 10 and 8 amino acid deletions, respectively, in the C-terminal tail of MA. The N-terminal myristylation site (N-Myr), nuclear export signal (NES), and nuclear
localization sequences (NLS) are denoted in addition to the labeled functional domains. (B and C) Molecular modeling of N-terminal basic domain mutations and
C-terminal deletions, respectively. The model was generated with PyMol software (DeLano Scientific LLC.) based on coordinates from Hill et al. (1996).
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whereby a subtle conformational change in MA exposes the
myr moiety (Ono et al., 2004; Scarlata et al., 1998; Spearman et
al., 1997; Tang et al., 2004; Zhou and Resh, 1996). Exposure of
the myr group anchors Pr55Gag into the lipid rafts. Interactions
between Pr55Gag, PI(4,5)P2 , and viral RNA at lipid rafts have
been hypothesized to be important for the oligomerization of
Pr55Gag (Ono et al., 2007). Viral envelope (Env) is then recruited
to the lipid raft domains and actively packaged into newly
forming virions, via an interaction between MA and the long
cytoplasmic tail of the Env transmembrane subunit (gp41CT)
(Bhattacharya et al., 2006).
Structural analyses of MA demonstrate that the protein
consists of five alpha-helical domains, four of which form an
N-terminal globular domain capped by a mixed beta-sheet
(Hill et al., 1996; Massiah et al., 1996). This beta-sheet region,
in conjunction with the exposed myr group is thought to have
direct contact with membranes. The C-terminal fifth helix
extends away from the globular head. Both NMR and
crystallographic studies support the notion that MA forms
trimers in solution, but it is unclear whether MA remains a
trimer when associated with virions (Hill et al., 1996). Recent
NMR work suggests that MA forms a hexameric lattice on
cholesterol-rich membranes, with trimerization occurring at
the interface between three hexamer rings (Alfadhli et al., in
press). The gp41CT is thought to extend through the holes in
the MA lattice.In an attempt to further define regions in MA important for
the regulation of viral entry we analyzed mutations in both the
N-terminal basic domain and the C-terminal helix which have
been previously proposed to affect replication at an early entry
step (Casella et al., 1997; Yu et al., 1992). Two deletion muta-
tions in the C-terminus of MA, termed D9 and D10, were shown
previously to affect the ability of virus to propagate in a T-cell
line (Yu et al., 1992). Mutation D9 contains a deletion of aa 105–
114 and a Leu to Ile substitution at residue 104 while mutation
D10 harbors a deletion of aa 116–123 (Fig. 1). Yu et al. (1992)
determined that D9 and D10 did not affect assembly or later
post-entry steps in viral replication, and suggested that these
mutants are defective at the step of viral fusion.
We also considered two N-terminal basic domain mutations,
MA (R18G,K20I,R22A) and MA (K32I,H33L), which are
designated MA18,20,22 and MA32,33 (Fig. 1). These mutants
were previously shown to harbor an early entry defect in addition
to displaying an impaired ability to incorporate envelope
(Casella et al., 1997).
Our results indicate that the C-terminal mutations only mildly
affect infectivity and fusion, and these defects are attributable to
corresponding reductions in envelope incorporation. In contrast,
the N-terminal mutations induce severe impairments in
infectivity, fusion, and envelope incorporation. Truncation of
the gp41CT rescued the phenotype of one of the C-terminal
deletions, but was unable to correct the defect resulting from the
N-terminal mutations.
Fig. 2. Effect of N-terminal and C-terminal mutants on infectivity. Equivalent
amounts of virus, based on p24 ELISA, were used to infect MAGI-5 (CD4+,
R5+, X4+) cells in triplicate. β-gal activity was measured 40 h post transfection
by counting blue cells. Studies were performed with viruses with or without
C-terminal truncation of gp41 (CTD). Values are reported as a percentage of WT
(134) infectivity.
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Characterization of infectivity defects induced by N- and
C-terminal MA mutations
We chose to analyze four different MA mutants which were
proposed in previous studies to be defective at an early entry step
in viral replication (Casella et al., 1997; Yu et al., 1992). Two
mutations, MA18,20,22 and MA32,33, are in the N-terminal
globular head region, while D9 andD10 are 10 and 8 aa deletions
in the extended C-terminal tail of MA, respectively. The
mutations are shown schematically in relation to other known
functional domains in MA (Fig. 1A). Molecular modeling of
MA illustrates that these mutations represent two distinct
domains of the MA protein (Figs. 1B and C). It is interesting
to note that the N-terminal MA mutations are located in the
solvent-exposed β-sheet which contains the membrane-inter-
acting basic domain (Freed et al., 1994; Hill et al., 1996;Massiah
et al., 1996).
In order to study these mutations, the mutant MA domains
were subcloned into the p134 proviral backbone with an R5 Env,
to insure that studies of infectivity, fusion, and envelope
incorporation were performed in the context of the same Env
and other viral proteins (Kaushik and Ratner, 2004). Consistent
with findings from previous reports, immunoprecipitation of
virus pelleted through a 20% sucrose cushion with AIDS patient
sera showed that Gag protein synthesis and processing were not
significantly affected by the MA mutations (data not shown).
Viral replication was measured in a single-cycle assay, by
infecting MAGI-5 cells with equal amounts of virus, as
measured by p24 ELISA (Fig. 2). Infectivity of D9 and D10
was reduced to 35% and 25% of wild-type levels, respectively
(Fig. 2A), but the infectivity of MA18,20,22 andMA32,33 were
more severely affected (Fig. 2B). Avirus, which harbors a Leu to
Glu change in MA at position 12 (L12E), shown to be defective
in packaging full-length envelope, was used as a negative
control (Freed and Martin, 1996). The level of L12E infectivity
was reduced to approximately 10% of wild-type levels. The
results from the N-terminal mutations are consistent with levels
of infectivity measured in a similar assay (Casella et al., 1997).
However, our infectivity data for the D9 and D10mutants differs
from those previously reported (Yu et al., 1992). That study
showed that both C-terminal deletion mutants caused significant
delays in a long-term replication assay in the Sup-T1 T-cell line.
In addition, the phenotype of D10 was more severe than that of
D9.
N and C-terminal mutants are defective in virus-dependent
fusion
In order to test the hypothesis that the N-terminal and C-
terminal mutations block replication at an early entry step, we
analyzed the ability of these mutant viruses to induce fusion
between cells expressing CD4 and CCR5 co-receptor. We
employed a quantitative virus-dependent fusion assay to
measure fusion by 134 wild-type virus, as well as by D10,
MA 18,20,22, and MA 32,33 mutant viruses (Fig. 3) (Pontow etal., 2004). L12E virus and an envelope-deficient (Env-) virus
were used as negative controls in these experiments. The fusion
assays yielded results that are consistent with the MAGI-5
infectivity data. D10 induced approximately 50% of wild-type
fusion levels (Fig. 3A), while levels of fusion induced by MA
18,20,22 and MA32,33 were reduced to 25% and 20% of wild-
type levels, respectively (Fig. 3B).
In an effort to eliminate the possibility that the N-terminal
mutations affected the intrinsic fusion activity of the viral
envelope, we used an envelope-dependent cell–cell fusion assay
to evaluate envelope protein function. Transfection of an Env-
proviral clone resulted in no detectable fusion activity. In
contrast, the envelope-dependent fusion activity induced by
MA18,20,22 and MA32,33 mutant proviruses was not sig-
nificantly different from that induced by the WT proviral clone
(data not shown).
C-terminal matrix mutants display mild defects in envelope
incorporation
Various mutations in MA have been shown to abrogate the
ability of newly assembled virions to incorporate viral envelope.
This is one possible explanation for the fusion defects induced
by the N- and C-terminal mutants. Although, the initial
characterization of the D9 and D10 mutant viruses maintained
that the levels of viral envelope incorporated were unaffected,
the authors examined only the levels of envelope present in virus
pelleted through a sucrose cushion (Yu et al., 1992).
Fig. 3. N and C-terminal mutants are defective in fusion. Equivalent amounts of virus, based on p24 ELISA, were added to a 1:1 mixture of U87.CD4.CCR5.GFP cells
expressing T7 polymerase or carrying the β-galactosidase gene under the regulation of the T7 promoter. Studies were performed with viruses with or without C-
terminal truncation of gp41 (CTD). (A) Fusion of WT (p134) and the D10 mutant virus. Experiments were done in triplicate and values are reported as relative levels of
β-galactosidase (β-gal) activity compared to p134 wild type (134WT). Avirus lacking envelope (dEnv) was used as a control. (B) Fusion of N-terminal mutants. Error
bars are derived from triplicate measurements of a representative experiment of a total of 5 independent experiments.
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lically labeled transfected 293T cells were harvested, pelleted
through a sucrose cushion, and analyzed by centrifugation
through a linear 20–60% sucrose density gradient. The radio-
activity levels and densities of the gradient fractions are shown
graphically in Fig. 4A.Mature particles have been shown to have
a density of approximately 1.14–1.16 g/ml (Tang et al., 2003).Fig. 4. C-terminal matrix mutants display mild defects in envelope incorporation. Me
was pelleted through a sucrose cushion, resuspended and centrifuged through 20–60
collected from top to bottom. The range of peak fraction densities is shown,
immunoprecipitated from peak fractions with pooled AIDS patient sera (numbered ab
Capsid, and gp120 Env are shown. Sizes of molecular weight markers are shown t
densitometry are shown.Peak fractions with densities between 1.12 and 1.16 g/ml were
collected and immunoprecipitated with pooled AIDS patient
sera. The immunoprecipitated fractions were resolved by SDS-
PAGE (Fig. 4B). While Gag synthesis and processing were
found to be unaffected by the mutations, densitometric analysis
of the gp120 (Env) to p24 (Gag) ratios in mutant compared to
wild-type virions revealed that D9 and D10 have mild defects intabolically-labeled virus produced from 134 (WT), D9 and D10 proviral clones
% sucrose density gradients. (A) CPM of 1 ml sucrose gradient fractions 1–16,
as measured by refractometry. (B) SDS-PAGE analysis of viral proteins
ove each lane according to fraction number). Bands delineating p17 Matrix, p24
o the left of the gel. (C) gp120:p24 ratios from peak fractions as calculated by
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envelope incorporation of the C-terminal mutants were similar to
the impairment of infectivity (Fig. 2A) and fusion (Fig. 3A).
N-terminal matrix mutants display severe defects in envelope
incorporation
Sucrose density gradient analysis was used to examine the
levels of homologous envelope in mature MA18,20,22 and
MA32,33 mutant virions (Fig. 5A). Gag processing was un-
affected by the mutations (Fig. 5A), however comparisons of
gp120:p24 ratios demonstrated that the N-terminal mutations are
severely impaired in their ability to incorporate envelope (Fig.
5B). These results are consistent with envelope incorporation
data presented previously (Casella et al., 1997).
Truncation of gp41CT rescues infectivity of one C-terminal
mutant, but not N-terminal MA mutations
Several lines of evidence suggest that an interaction between
MA and gp41CT regulates viral fusion and envelope incorpora-
tion (Murakami et al., 2004; Wyma et al., 2004). Truncation of
the gp41CT has been shown to rescue the infectivity of virions
harboring the L12E mutation in MA, which is known to
abrogate envelope incorporation into viral particles. In addition,
truncation of the cytoplasmic tail of gp41, in the context of
uncleaved Gag restores the fusion defect exhibited by immature
particles. We tested the hypothesis that altered MA-gp41
interactions are responsible for the N- and C- terminal MA
mutant phenotypes by introducing a stop codon into the gp41
coding sequence such that the C-terminal 144 aa of gp41 are not
translated. We then examined the effects of this truncation (gp41
CTD) on viral infectivity (Fig. 2). Our results demonstrate that
D10CTD rescues infectivity of D10, whereas D9CTD does not
(Fig. 2A). Truncation of gp41CT was unable to rescue theFig. 5. N-terminal MA mutants display severe defects in envelope incorporation. Me
envelope deficient (Env-) proviral clones was pelleted through a sucrose cushion,
Immunoprecipitation of peak fractions was performed with AIDS patient sera. Lane n
by densitometry.infectivity defect induced by the MA18,20,22 and MA32,33
mutations (Fig. 2B).
Virus-dependent fusion assays were also performed with
CTD mutants of MA18,20,22 and MA32,33 (Fig. 3B).
Compared to MA18,20,22 and MA32,33, the CTD mutants
increased virus-dependent fusion activity 2.9-fold and 3.7-fold,
respectively, based on four independent experiments (two tailed
t test pb0.001). In each case, truncation of gp41 rescued the
defect in virus-dependent fusion activity. This suggests that the
defect in gp120 incorporation in MA18,20,22 and MA32,33
viruses was overcome by truncation of gp41. Moreover, it
suggests that defects in infectivity of the CTDmutants are due to
a post-fusion event.
Discussion
HIV-1 MA is involved in many processes relating to both
entry and assembly of the virus (Bukrinskaya, 2004; Freed,
1998; Scarlata and Carter, 2003). Recently MA has been
proposed to have an inhibitory function in relation to HIV-1
fusion, especially in the context of immature virions (Murakami
et al., 2004; Wyma et al., 2004). Our studies attempt to further
explore the role ofMA in the regulation of viral entry and fusion.
In an effort to define potential fusion regulatory domains in MA,
we analyzed mutations that have been hypothesized to block
replication at an entry step.
Deletion mutations in the C-terminus of MA, D9 and D10,
were shown previously to severely affect the ability of virus to
propagate in a T-cell line (Yu et al., 1992). The replication defect
demonstrated by D9 mutant virus was less severe than that of
D10 mutant virus, but a delay in replication was still
appreciated. Analysis of the assembly stages of HIV-1
replication suggested that these mutants did not affect the
viral synthesis of Gag, proteolytic cleavage of Gag, or assembly
and release of virus.tabolically-labeled virus produced from 134 (WT), MA18,20,22, MA32,33 and
resuspended and centrifuged through 20–60% sucrose density gradients. (A)
umbers correspond to gradient fraction numbers. (B) gp120:p24 ratio calculated
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regarding the D9 and D10 mutations (Yu et al., 1992). A single
cycle infectivity assay suggests that while both D9 and D10 are
replication deficient, the defects were relatively mild. Both D9
and D10 exhibited three to four-fold reductions in infectivity
(Fig. 2A). Furthermore, studies of mature virions indicate that
the assembly of the mutant virions is affected by the C-terminal
deletions in MA. Sucrose density gradient analysis and
immunoprecipitation with AIDS patient antisera indicate that
Gag protein synthesis and processing appear to be unaffected,
but envelope incorporation is reduced (Figs. 4B and C).
Data from Yu et al. (1992) showed that the C-terminal
mutations did not affect later post-entry steps in the viral life
cycle such as DNA synthesis. Thus, it was hypothesized that D9
and D10 affected an early entry step in viral replication.
Interestingly, a sequence, AADTGHSSQV, deleted in mutant
D10, is highly conserved among HIV-1 strains and exhibits high
homology to sequences in VP1 of picornaviridae which have
been implicated in poliovirus penetration of host cells (Fricks
and Hogle, 1990). Virus-dependent fusion assays demonstrate a
defect induced by the D9 and D10 mutations (Fig. 3A), but this
fusion defect correlates well with the reduced levels of envelope
incorporated into the mutant virions (Fig. 4C).
The basic residues in the solvent exposed side of the N-
terminal MA β-sheet also appear to play a role in HIV entry.
During their initial characterization, both the MA18,20,22 and
MA32,33 exhibited severely reduced infectivity, reduced
expression of intracellular viral proteins and only mild defects
in Gag processing (Casella et al., 1997). In addition, the mutant
viruses were unable to reverse-transcribe their RNA, suggesting
that there was a defect in an early replication step, prior to
synthesis of DNA. Interestingly, these mutants were also
defective in HIV Env incorporation into the virions.
Our results confirmed the severe replication block induced by
the N-terminal mutations (Fig. 2B). These viruses were also
unable to induce fusion (Fig. 3B) and sucrose density gradient
analysis confirms that both MA18,20,22 and MA32,33 are
defective in envelope incorporation (Fig. 5). Despite the inability
of the N-terminal mutations to incorporate HIV-1 envelope,
Casella et al. (1997) determined that these mutants could still
incorporate a heterologous retroviral envelope glycoprotein
from amphotropic murine leukemia virus (Casella et al., 1997).
However, these pseudotyped viruses were still replication
deficient, suggesting that the entry defect is not solely related
to the HIV MA and HIV Env interaction. Interestingly, while
truncation of the gp41CT rescues the fusion defects induced by
the N-terminal mutations (Fig. 3B), thus demonstrating restora-
tion of Env to the surface of the virions, the CTD mutation
cannot rescue the defect in infectivity (Fig. 2B). Data from our
lab and from other studies of HIV-1 and SIV envelope suggest
that envelope with truncated cytoplasmic tails is incorporated by
a passive packaging mechanism independent of MA interaction
with Env (Guern and Levy, 1992; Johnston et al., 1993;
Salzwedel et al., 1993; Sauter et al., 1996). Since envelope
incorporation is restored, but the replication defect persists, this
would suggest that an additional post-entry defect is partly
responsible for the N-terminal MA mutant replication block.Taken together, the data presented in this report reveal that the
major replication block for both the N-terminal and C-terminal
mutations is during envelope incorporation, rather than at an
early entry step.
It is likely that the D9 and D10 mutations affect the ability of
Pr55Gag to interact directly with gp41CT or with an additional
host bridging molecule. The large deletions in the extended 5th
helix may alter the conformation of the Pr55Gag precursor and
impair protein–protein interactions. It is also possible that these
mutations affect the ability of Pr55Gag to oligomerize at the
membrane. This scenario also applies to the N-terminal
mutations, but it is appealing to consider other mechanisms
by which mutations in the basic domain impair envelope
incorporation. There is strong evidence to support a role for the
basic domain in membrane binding to acidic phospholipids and
neutralization of the charge in this domain may inhibit
membrane adherence by Pr55Gag, and inhibit assembly (Freed
et al., 1994, 1995; Ono et al., 2000; Scarlata et al., 1998).
Additionally, there is good evidence to implicate the basic
domain of MA in the interaction with the lipid raft associated PI
(4,5)P2 (Ono et al., 2004; Saad et al., 2006). This interaction
has been shown to aid in targeting Pr55Gag to lipid raft domains
and, importantly, to mediate the myristyl switch which exposes
the myr group and anchors Pr55Gag into the membrane. NMR
studies demonstrate that PI(4,5)P2 interacts directly with the
basic patch in MA. Interestingly, NMR and mass spectroscopic
footprinting studies have suggested that MA residues 32 and 33
are important in mediating the interaction between MA and PI
(4,5)P2. Hence, it is possible that the N-terminal mutations in
Gag affect the ability of Pr55Gag to target to the plasma
membrane and associate with PI(4,5)P2 at rafts. This could
impair the myristyl switch, prevent adequate oligomerization,
and potentially redirect Gag to other intracellular compart-
ments, all of which adversely impact envelope incorporation.
Future studies will attempt to further define the entry block
exhibited by the N-terminal MA mutations and elucidate the




The GB107, an envelope deficient proviral clone and mole-
cular clones harboring theMA18,20,22 andMA32,33mutations
within the GB107 backbone were the kind gifts of A.
Panganiban (Buchscacher and Panganiban, 1992; Casella et
al., 1997). P. Spearman kindly donated plasmids containing the
D9 and D10 MA mutations in the HXB2R3 proviral back-
ground. The mutant matrix regions were PCR-amplified from
the proviral DNAs using standard techniques. Specifically, we
amplified a region of gag extending from the BssHII to SphI
restriction sites which includes the MA coding region. The PCR
products were TA cloned into the pGEMT-easy vector
(Promega) and the BssHII–SphI gag fragments were subse-
quently excised by restriction digestion. The mutant gag
cassettes were subcloned into p134, an NL4-3 proviral clone
53A.K. Bhatia et al. / Virology 369 (2007) 47–54backbone including gag derived from X4-strain HXB2 and env
derived from R5-strain YU2, as described previously (Kaushik
and Ratner, 2004). Envelope glycoprotein gp41 C-terminal
deletion (CTD) mutants were generated by introducing a stop
codon to produce TM lacking the C-terminal 144 amino acids
(Freed and Martin, 1995; Murakami et al., 2004; Wyma et al.,
2004). The BssHII–SphI gag fragment of gp41-CTD was
substituted with the gag cassettes of MA18,20,22, MA32,33,
D9, or D10.
Cell culture and transfection
Proviral clones were transfected into 293Tcells with TransIT-
LT1 (Mirus) according to the manufacturer's protocol. 293T
cells were maintained in DMEM supplemented with 10% Fetal-
Clone III (Gibco), 4 mM L-glutamine, and penicillin–strepto-
mycin. MAGI-5 reporter cells were maintained in supplemented
DMEM with puromycin, hygromycin, and G418 (Pirounaki et
al., 2000). U87 (CD4+, R5+) were maintained in DMEM
supplemented with 10% Fetal-Clone III, 4 mM L-glutamine,
penicillin–streptomycin, puromycin and G418 (Pontow et al.,
2004).
Western blotting and immunoprecipitation
HIV-1 proteins were immunoprecipitated and detected by
western blot using pooled HIV-1 patient sera. Anti-p17 and anti-
p24 polyclonal rabbit antisera were also used in western blot
assays (Spearman et al., 1994).
Infectivity assay
MAGI-5 cell lines (HeLa β-galactosidase+, CD4+, CCR5+)
were plated in a 96 well plate at a density of 104 cells per well.
The cells were then infected with 25 ng, as determined by p24
ELISA (Beckman-Coulter, Fullerton, CA), of virus in triplicate.
Virus was removed 40 h post-infection and the cells were then
fixed with PBS containing 2% formaldehyde (Sigma, St. Louis,
MO) and 0.2% glutaraldehyde (Sigma, St. Louis, MO) for 5 min
at room temperature. Cells were washed in PBS and stained with
X-gal (Calbiochem San Diego, CA) for 35 to 55 min at 37 °C.
Cells were then washed again and the number of blue cells per
well was counted.
Virus-dependent fusion assay
The virus-dependent fusion assay was performed as
described previously (Pontow et al., 2004). Briefly, equivalent
amounts of virus particles as determined by p24 antigen ELISA
(Beckman-Coulter, Fullerton, CA) were mixed at 37 °C with
U87 glioma cells expressing CD4 and a CCR5-GFP fusion
protein. U87.CD4.CCR5.GFP cells were serum-starved for 24 h
and then they were infected with recombinant vaccinia virus
with β-galactosidase under the control of the T7 promoter
(vCB21R), or recombinant vaccinia virus expressing T7
polymerase (vPT7-3). Cells were infected overnight, harvested
by trypsin treatment, resuspended in HBSS with 3% fetal calfserum, and mixed (1:1) in triplicate wells of a 96-well plate, and
then virus and 20 μg/ml DEAE-dextran were added. Fusion
reactions were incubated for 3 h at 37 °C. Fusion was stopped by
the addition of NP-40 to a final concentration of 1% and β-
galactosidase activity was determined using chlorophenol red-
β-D-galactopyranoside (Calbiochem, San Diego, CA) as sub-
strate, and reading the absorbance at 579 nm.
Envelope-dependent fusion assay
WT and mutant proviral clones were transfected into BSC40
cells. After 24 h, these cells were infected with vPT7-3. An equal
number of U87.CD4.CCR5.GFP cells were infected with
vCB21R. Cells were cultured overnight, harvested by trypsin
treatment, washed and mixed in triplicate wells of a 96-well
plate. Cell–cell fusion reactions were incubated for 3 h at 37 °C,
and β-galactosidase activity in cell lysates determined.
HIV-1 sucrose gradient analysis
293T cells plated in 100 mm dishes were transfected with
10 μg of proviral DNA using TransIT (Mirus) transfection
reagent as described in the manufacturer's protocol. Transfec-
tion media was removed 1 day following transfection and the
cells were then metabolically labeled with 200 μl of 35-S
Translabel (MPbio) in cys(−)/met(−) DMEM supplemented
with 10% dialyzed fetal calf serum (Washington University
Tissue Culture Center). Supernatants containing radio-labeled
virus were then harvested 48–60 h later. The viral supernatants
were subsequently cleared of cellular debris by centrifugation
for 5 min at low speed. Viruses were pelleted through a 20%
sucrose cushion via ultracentrifugation at 45000 rpm for 45 min
in an SW55Ti rotor (Beckman). The pelleted virus was then
resuspended in 700 μl of OptiMEM (Invitrogen) and gently
layered at the top of a 16 ml 20–60% sucrose gradient. The
gradient was then centrifuged at 26000 rpm in an SW28 rotor
(Beckman) for 24 h, and 1 ml fractions were collected from
the top of the gradient. The gradient fractions were analyzed
using a refractometer (Fisher Scientific Co.) and radioactivity
quantified using a scintillation counter (Beckman-Coulter). The
density of each fraction was calculated using the formula
ρ=2.6496 η −2.5323, where ρ is density (g/ml) and η is the
refractive index (Forshey et al., 2002; Tang et al., 2003). Peak
fractions with densities greater than 1.12 g/ml but less than
1.16 g/ml were then immunoprecipitated overnight with pooled
AIDS patient sera at 1:100 dilution. Immunoprecipitated
samples were then resolved by electrophoresis through a 15%
SDS-PAGE gel. The gel was subsequently fixed, dried, and
exposed to a phosphoimager screen for 24 h. The screen was
then analyzed by the STORM phosphoimager system and
quantified using MacQuant imaging software.
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